Risvutatug rezetecan
- Listing at source
- Listed
- Drug name
- Risvutatug rezetecan
- risvutatug rezetecan
- Risvutatug rezetecan
- Risvutatug Rezetecan
- Risvutatug rezetecan (Ris-Rez)
- risvutatug rezetecan ris rez
- FDA ingredient codes (UNII)
- 7T9A6CKG67
Related records
Trials (5)
- A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases
- A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
- A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)
- A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]
- A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)